Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00108914 · ClinicalTrials.gov registry record · Phase 3

Perennial Allergic Rhinitis Study In Pediatric Subjects

A Phase 3 study of Rhinitis, Allergic, Perennial, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 3
Development phase
558
Enrollment target
20
Study locations

NCT00108914: Completed Phase 3 study of Rhinitis, Allergic, Perennial, sponsored by GlaxoSmithKline.

NCT00108914 is a Phase 3 study of Rhinitis, Allergic, Perennial that has completed, run by GlaxoSmithKline. The registered enrollment target is 558 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (28% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00108914, a Phase 3 study of Rhinitis, Allergic, Perennial, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 3
Development phase
558 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine if the investigational drug is effective and safe in children with perennial allergic rhinitis.

Interventions

  • DRUG GW685698X

Study Locations (20)

California

  • GSK Investigational Site - Costa Mesa
  • GSK Investigational Site - Cudahy
  • GSK Investigational Site - Long Beach
  • GSK Investigational Site - Long Beach
  • GSK Investigational Site - Orange
  • GSK Investigational Site - Riverside
  • GSK Investigational Site - Sacramento
  • GSK Investigational Site - San Diego
  • GSK Investigational Site - San Diego
  • GSK Investigational Site - Walnut Creek

Colorado

  • GSK Investigational Site - Denver
  • GSK Investigational Site - Denver
  • GSK Investigational Site - Englewood

Georgia

  • GSK Investigational Site - Gainesville
  • GSK Investigational Site - Lawrenceville
  • GSK Investigational Site - Stockbridge

Louisiana

  • GSK Investigational Site - Metairie
  • GSK Investigational Site - Shreveport

Florida

  • GSK Investigational Site - Coral Gables

Maryland

  • GSK Investigational Site - Baltimore

Trial Details

FieldValue
Enrollment Target 558 participants
Start Date 2005-02
Est. Completion 2005-11
Phase Phase 3
GlaxoSmithKline

1,345 total trials

What the finished NCT00108914 record still lists

NCT00108914 is an interventional study that assigns participants to a tested intervention. The registered 558 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (28% lower).

The record links to 1 condition, with Rhinitis, Allergic, Perennial appearing as the primary indexed condition, and to 1 intervention - of which GW685698X is the first listed.

NCT00108914 names 20 study sites across 6 states, led by California, Colorado, Georgia.

Frequently Asked Questions

What is clinical trial NCT00108914 about?

NCT00108914 is a clinical study titled "Perennial Allergic Rhinitis Study In Pediatric Subjects". The purpose of this study is to determine if the investigational drug is effective and safe in children with perennial allergic rhinitis.

What is the current status of trial NCT00108914?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 558 participants. The study started on 2005-02. Estimated completion is 2005-11.

What conditions does trial NCT00108914 study?

This clinical trial studies the following conditions: Rhinitis, Allergic, Perennial.

What interventions are being tested in trial NCT00108914?

The interventions under investigation include: GW685698X (DRUG).

Who is sponsoring clinical trial NCT00108914?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00108914 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rhinitis, Allergic, Perennial

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00108914's enrollment target sits among peer trials

558 673rd of 2000 higher than 1,327 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT07173751 · 558 participants · Phase 3

    ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

  • NCT05708885 · 557 participants · NA

    Striated Esophageal Motor Function Modulation in Health and Disease

  • NCT04661358 · 560 participants · Phase 3

    Fenofibrate for Prevention of DR Worsening

  • NCT05473871 · 560 participants · NA

    Enhancing Capacity in Churches to Implement PA Programs

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00108914, the US trial registry maintained by the National Library of Medicine. NCT00108914 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.